Stefan Kraemer

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2016 · 357 citations

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Nadia Harbeck, Oleg Gluz, Matthias Christgen et al. · Journal of Clinical Oncology · 2017 · 143 citations

PREPUBERTAL HIGH FLOW PRIAPISM: INCIDENCE, DIAGNOSIS AND TREATMENT

Bjoern G. Volkmer, Stefan Kraemer, J. Goerich et al. · The Journal of Urology · 2001 · 43 citations

Breast conservative surgery and local recurrence

Mahdi Rezai, Stefan Kraemer, Rainer Kimmig et al. · The Breast · 2015 · 30 citations · Full text

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

Nadia Harbeck, Oleg Gluz, Matthias Christgen et al. · Journal of Clinical Oncology · 2015 · 18 citations

Endocrine Oncology, Breast Oncology, Adapt Her2+/h +14